Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Bought by Barclays PLC

Barclays PLC lifted its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 149.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 52,545 shares of the company’s stock after acquiring an additional 31,467 shares during the quarter. Barclays PLC’s holdings in Soleno Therapeutics were worth $2,652,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of SLNO. Amalgamated Bank acquired a new stake in Soleno Therapeutics in the second quarter valued at approximately $31,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Soleno Therapeutics during the 3rd quarter valued at $155,000. Curi RMB Capital LLC purchased a new stake in Soleno Therapeutics during the 3rd quarter worth $202,000. Intech Investment Management LLC acquired a new position in Soleno Therapeutics in the 3rd quarter worth $262,000. Finally, Fred Alger Management LLC purchased a new position in Soleno Therapeutics in the 3rd quarter valued at about $310,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Trading Down 0.4 %

Shares of SLNO opened at $44.77 on Wednesday. Soleno Therapeutics, Inc. has a 52 week low of $35.70 and a 52 week high of $60.92. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -13.48 and a beta of -1.47. The stock has a 50 day moving average of $52.75 and a 200-day moving average of $49.17.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22). On average, sell-side analysts predict that Soleno Therapeutics, Inc. will post -3.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

SLNO has been the topic of a number of analyst reports. Robert W. Baird reaffirmed an “outperform” rating and set a $72.00 target price on shares of Soleno Therapeutics in a research report on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Soleno Therapeutics in a report on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Soleno Therapeutics in a research report on Friday, September 20th. Oppenheimer raised their price target on shares of Soleno Therapeutics from $65.00 to $73.00 and gave the stock an “outperform” rating in a research report on Monday, October 28th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $74.00 price target on shares of Soleno Therapeutics in a report on Monday, December 2nd. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Soleno Therapeutics currently has a consensus rating of “Buy” and an average price target of $74.83.

Insider Activity

In other Soleno Therapeutics news, CFO James H. Mackaness sold 8,077 shares of Soleno Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $49.43, for a total value of $399,246.11. Following the completion of the transaction, the chief financial officer now directly owns 119,172 shares in the company, valued at $5,890,671.96. The trade was a 6.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kristen Yen sold 3,108 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total value of $153,628.44. Following the transaction, the insider now directly owns 81,465 shares of the company’s stock, valued at $4,026,814.95. This trade represents a 3.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 32,818 shares of company stock valued at $1,622,194. Company insiders own 12.30% of the company’s stock.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.